Facebook RSS Twitter
Wed, Sep 17, 2025
Facebook RSS Twitter
Home City: San Marino

City: San Marino

San Marino News – business, entertainment and technology news from San Marino, California

Advanced Phase I and Phase II Studies of Targeted Gene Delivery Confirm That Rexin-G Impacts Survival in Chemotherapy-resistant Bone and Soft...

Cindy Holden -

FDA Fast Track Designation for the Treatment of Pancreatic Cancer Given to Rexin-G®

Valerie Gotten -

Rexin-G® Nano Particles Target Metastatic Cancers

Cindy Holden -

Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma

Valerie Gotten -

Beginners Luck, or Creative Artists of the First Rank? Epeius Bio Launches Rexin-G eBook Tutorial

Cindy Holden -

Rexin-G® Shrinks Metastatic Tumors and Triples Survival Time in Chemotherapy-Resistant Pancreatic Cancer

Cindy Holden -

Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine

Cindy Holden -

Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma

Cindy Holden -

Epeius Rexin-G Returns to The Big Apple: Clinical Trials for Pancreatic Cancer and Breast Cancer Open in Manhattan

Cindy Holden -

Epeius Biotech Reveals a New Generation of Tools for Medical Gene Delivery

Cindy Holden -

Rexin-G for Metastatic Cancer Aptly Highlighted by National Cancer Institute Journal

Cindy Holden -

FDA Grants Rexin-G from Epeius Biotechnologies a Third Orphan Drug Designation

Cindy Holden -

Epeius Biotechnologies’ Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for Osteosarcoma Treatment

Cindy Holden -

IV Infusions of Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity

Cindy Holden -

Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes

Cindy Holden -

Rexin-G Monotherapy Reveals Significant Biological Activity without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)

Cindy Holden -

ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity without Toxicity in Metastatic Pancreatic Cancer

Cindy Holden -

Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy

Cindy Holden -

Epeius Bio Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo

Cindy Holden -

As Targeted Gene Therapy Comes of Age in Clinical Medicine, Epeius Biotechnologies Applauds Their Academic Contemporaries

Valerie Gotten -

ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer

Cindy Holden -

FDA Approves the Opening of a Phase II Registration Protocol Using REXIN-G for Osteosarcoma

Cindy Holden -

Epeius Biotechnologies Leads with Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference...

Cindy Holden -

California Biotech Company Takes Aim at Pancreatic Cancer With an Advanced Phase I/II Clinical Trial

Cindy Holden -

Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics

Valerie Gotten -

Epeius Biotechnologies Gains FDA Approval for Two New Clinical Trials Using Rexin-G(TM) for Breast Cancer and Sarcoma

Valerie Gotten -

Epeius Biotechnologies to Present the Advent of Tumor Targeting Technology at C21 BioVentures Conference

Cindy Holden -

Japanese Study Confirms Safety and Efficacy of Intravenous Rexin-G

Cindy Holden -

Rexin-G, The World’s First Tumor-Targeted Gene Therapy Vector, Stymies Metastatic Cancer

Valerie Gotten -

FEATURED NEWS

© 2000-2025 Neotrope®